stockrowAccendra Health, Inc.
ACH Healthcare Medical Distribution
Accendra Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.8 billion, up 3.06% from fiscal 2024.
- Revenue
- −10.1%
- EPS
- +89.7%
- Free cash flow
- −1,624.8%
- Total debt
- −13.1%
Quarter to June 2026, against a year earlier
Follow ACH
Alert me
Accendra Health, Inc. (ACH) Piotroski F-score
Accendra Health, Inc.'s Piotroski F-score for fiscal 2025 is 2 out of 9: 2 of nine tests of profitability, leverage and efficiency passed, down from 4 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 2 | (2.00) |
| FY2024 | 4 | 0.00 |
| FY2023 | 4 | 0.00 |
| FY2022 | 4 | (3.00) |
| FY2021 | 7 | 1.00 |
| FY2020 | 6 | 1.00 |
| FY2019 | 5 | 2.00 |
| FY2018 | 3 | (1.00) |
| FY2017 | 4 | (3.00) |
| FY2016 | 7 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (30.97%) | (7.44%) | Fail | 0 |
| Positive operating cash flow | (101.79m) | 161.50m | Fail | 0 |
| Rising return on assets | (30.97%) | (7.44%) | Fail | 0 |
| Cash flow above net income | 998.85m | 524.18m | Pass | 1 |
| Falling long-term leverage | 0.51 | 0.37 | Fail | 0 |
| Rising current ratio | 0.58 | 1.09 | Fail | 0 |
| No new shares issued | 76,897,000 | 76,741,000 | Fail | 0 |
| Rising gross margin | 46.68% | 47.77% | Fail | 0 |
| Rising asset turnover | 0.78 | 0.55 | Pass | 1 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 2 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| COSM Cosmos Health Inc. compare | 5 |
| AHG Akso Health Group Sponsored ADR compare | 5 |
| YI 111, Inc. Sponsored ADR compare | 5 |
| HSIC Henry Schein, Inc. compare | 5 |
| FOCL FocalTherics compare | 3 |
| HKPD Cellyan Biotechnology Co., Ltd compare | 3 |
| SNYRQ Synergy CHC Corp. compare | 2 |
| ACH Accendra Health, Inc. | 2 |
| MEDS DataMeds AI, Inc compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover